LifeMD, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 9B. OTHER INFORMATION
On November 24, 2025, Jessica Friedeman, Chief Marketing and Product Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 100,000 shares of the Company’s common stock, at various limit prices above the current market price of the Company’s common stock as of the plan adoption date, with such transactions to occur during sale periods beginning on or after March 23, 2026 and ending on the earlier of October 29, 2027 or the date on which all shares authorized for sale have been sold in conformance with the terms of the arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.